Us Advanced Therapy Medicinal Products Cdmo Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Advanced Therapy Medicinal Products are a class of biologic medicines that include gene therapies, somatic cell therapies, tissue-engineered products, and combinations thereof. CDMOs in this space provide end-to-end support spanning process development, clinical and commercial manufacturing, analytical testing, and regulatory services tailored to these complex modalities. The North American market commands the dominant global share of approximately 42.8%, driven by a dense ecosystem of biotechnology companies, academic medical centers, and favorable regulatory pathways through the FDA.

• •The global ATMP CDMO market is estimated at approximately $7.73 billion in 2025, with North America representing roughly $3.3 billion
• •Advanced therapies constitute the fastest-growing segment within the broader pharmaceutical CDMO market, which reached approximately $173.7 billion in 2025 overall
• •The underlying ATMP product market itself is substantially larger, estimated at approximately $16.6 billion in 2025

A robust pipeline of cell and gene therapy candidates in clinical development is a primary catalyst, as biopharmaceutical sponsors increasingly rely on CDMOs to access specialized manufacturing infrastructure without building costly in-house capacity. Regulatory momentum, including expedited designations and an expanding list of approved ATMP products, is creating sustained demand for manufacturing partnerships across both clinical and commercial stages. Significant capital inflows into biotechnology, particularly in the United States, continue to fund programs that require CDMO services from early development through post-approval supply.

• •Rapid expansion of approved cell and gene therapies is generating long-term commercial manufacturing demand
• •High levels of biopharmaceutical R&D investment in the United States underpin outsourced advanced therapy manufacturing growth
• •Specialized manufacturing requirements for viral vectors, cell therapies, and personalized medicines create high barriers to entry favoring established CDMOs

North America's roughly 42.8% share of the global ATMP CDMO market reflects concentrated demand from U.S.-based biotechnology hubs including the San Francisco Bay Area, Greater Boston, and San Diego, as well as growing activity in Canada. Within the market, services span process development, clinical-scale manufacturing, and commercial-scale supply, with cell therapy and gene therapy manufacturing representing the highest-growth subsectors. Compared to Europe and Asia-Pacific, North America benefits from deeper pools of venture capital, a larger installed base of FDA-approved advanced therapy manufacturing facilities, and a regulatory environment that encourages innovation.

• •Gene therapy and cell therapy manufacturing dominate ATMP CDMO service demand within North America
• •The region's market leadership is underpinned by the highest per-capita biopharmaceutical R&D spending globally
• •Canada and Mexico contribute to North American market volume, though the United States accounts for the overwhelming majority of regional revenue

What are the recent trends and outlook?

The market is expected to sustain double-digit annual growth through the early 2030s, with projections varying by source from approximately 14.8% to 18.8% CAGR globally, implying continued strong expansion for the North American share. Key emerging trends include increasing adoption of single-use and modular manufacturing technologies, growing demand for end-to-end integrated services, and the rise of decentralized or point-of-care manufacturing models for personalized cell therapies. As the pipeline of late-stage ATMP candidates advances toward commercialization, CDMOs that demonstrate regulatory compliance, manufacturing reliability, and scalable capacity will be positioned to capture the greatest value.

• •Global ATMP CDMO market projections converge on sustained strong growth, with a 16.87% CAGR taking the market well beyond $10 billion by the early 2030s
• •Integration of digital quality management and continuous manufacturing technologies is accelerating efficiency across CDMO operations
• •Personalized medicine and allogeneic cell therapy platforms are driving new manufacturing paradigms and CDMO service offerings